This phase III trial is trying to understand how safe and effective an adjuvant therapy is compared to active surveillance in patients that have had their hepatocellular (liver) cancer removed or destroyed and who have a high risk of their cancer coming back.
This trial is treating patients with hepatocellular (liver) cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Eligible patients will be randomised to receive adjuvant therapy with Atezolizumab and Bevacizumab, or active surveillance until disease recurrence or toxicity.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More